Articles By Anuja Singh
How Will New U.S. Drug Pricing Policies Reshape the Pharmaceutical Ecosystem?
Washington, D.C. — December 29, 2025 — Recent changes in U.S. drug pricing policies are fundamentally reshaping the…
ByHow Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for…
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in…
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and…
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to strengthen its pipeline,…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in…
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for…
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…
How Will New U.S. Drug Pricing Policies Reshape the Pharmaceutical Ecosystem?
Washington, D.C. — December 29, 2025 — Recent changes in U.S. drug pricing policies are fundamentally reshaping the…
How Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for…
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in…
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and…
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to strengthen its pipeline,…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in…
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for…
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…